Amarin Corporation PLC Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (40)

Latest Posts

About This Stock More About This Stock
Amarin Shares Have Downside To $3 On Patent Loss, Says Northland
Article By: The Fly
Thursday, September 3, 2020 8:20 AM EDT
An unfavorable Vascepa patent ruling from the Court of Appeals Federal Circuit can place the shares of Amarin in the $3 range, Northland analyst Carl Byrnes tells investors in a research note.
In this article: AMRN
Read
Amarin Sinks After Vascepa Patent Trial Judges Are Revealed
Article By: The Fly
Wednesday, September 2, 2020 10:42 AM EDT
Shares of Amarin moved lower after the judges were posted for the company's Federal Circuit appeal of the Vascepa patent invalidation versus generics.
In this article: AMRN
Read
Amarin Settlement With Apotex An 'Incremental Positive,' Says Stifel
Article By: The Fly
Wednesday, June 17, 2020 11:09 AM EDT
Stifel analyst Derek Archila reiterates his Hold rating on Amarin shares after the company settled with Apotex regarding its ANDA application for generic Vascepa.
In this article: AMRN Also: RDY, TEVA
Read
Hikma Receives FDA Approval For Generic Of Amarin's Vascepa
Article By: The Fly
Friday, May 22, 2020 7:42 AM EDT
Hikma Pharmaceuticals announced overnight that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA has received approval from the Food and Drug Administration for its Icosapent Ethyl Capsules, the generic equivalent to Amarin's Vascepa.
In this article: HKMPF, AMRN
Read
Northland Starts Amarin At Outperform Amid 'Major Paradigm Shift'
Article By: The Fly
Tuesday, May 5, 2020 11:00 AM EDT
Northland analyst Carl Byrnes initiated coverage of Amarin with an Outperform rating and $15 price target.
In this article: AMRN
Read

PARTNER HEADLINES

Latest Tweets for $AMRN

No tweets yet!